



Orexo Digital Therapeutics – Artificial Intelligence Driven Cognitive Behavior Therapies

Orexo is a Swedish specialty pharmaceutical company, founded in 1995.

Direct presence in the US with lead asset Zubsolv® (buprenorphine and naloxone sublingual tablet (CIII) for treatment of opioid dependence).

Orexo now offers a broad pipeline with multiple assets based on innovative drug delivery technologies and digital therapeutics.

In 2019 Orexo launched a new digital therapeutics division by licensing a portfolio of digital therapeutics for problematic drinking, opioid use disorder, and depression.

Digital therapeutics (DTx) delivers evidence-based therapeutic interventions to patients to prevent, manage, or treat depression and problematic drinking.

We believe our solutions can uniquely assist MCOs, Employers and IDNs in managing the substantial costs of mental/behavioral health disorders and improve lives.